Abstract:Arteriosclerosis, Thrombosis, and Vascular Biology, Ahead of Print. BACKGROUND:Atherosclerosis is the most common cause of cardiovascular diseases. Clinical studies indicate that loss-of-function ASGR1 (asialoglycoprotein receptor 1) is significantly associated with lower plasma cholesterol levels and reduces cardiovascular disease risk. However, the effect of ASGR1 on atherosclerosis remains incompletely understood; whether inhibition of ASGR1 causes liver injury remains controversial. Here, we comprehensively investigated the effects and the underlying molecular mechanisms of ASGR1 deficiency and overexpression on atherosclerosis and liver injury in mice.METHODS:We engineeredAsgr1knockout mice (Asgr1−/−),Asgr1andApoEdouble-knockout mice (Asgr1−/−ApoE−/−), and ASGR1-overexpressing mice on anApoE−/−background and then fed them different diets to assess the role of ASGR1 in atherosclerosis and liver injury.RESULTS:After being fed a Western diet for 12 weeks,Asgr1−/−ApoE−/−mice exhibited significantly decreased atherosclerotic lesion areas in the aorta and aortic root sections, reduced plasma VLDL (very-low-density lipoprotein) cholesterol and LDL (low-density lipoprotein) cholesterol levels, decreased VLDL production, and increased fecal cholesterol contents. Conversely, ASGR1 overexpression inApoE−/−mice increased atherosclerotic lesions in the aorta and aortic root sections, augmented plasma VLDL cholesterol and LDL cholesterol levels and VLDL production, and decreased fecal cholesterol contents. Mechanistically, ASGR1 deficiency reduced VLDL production by inhibiting the expression of MTTP (microsomal triglyceride transfer protein) and ANGPTL3 (angiopoietin-like protein 3)/ANGPTL8 (angiopoietin-like protein 8) but increasing LPL (lipoprotein lipase) activity, increased LDL uptake by increasing LDLR (LDL receptor) expression, and promoted cholesterol efflux through increasing expression of LXRα (liver X receptor-α), ABCA1 (ATP-binding cassette subfamily A member 1), ABCG5 (ATP-binding cassette subfamily G member 5), and CYP7A1 (cytochrome P450 family 7 subfamily A member 1). These underlying alterations were confirmed in ASGR1-overexpressingApoE−/−mice. In addition, ASGR1 deficiency exacerbated liver injury in Western diet–inducedAsgr1−/−ApoE−/−mice and high-fat diet–induced but not normal laboratory diet–induced and high-fat and high-cholesterol diet–inducedAsgr1−/−mice, while its overexpression mitigated liver injury in Western diet–induced ASGR1-overexpressingApoE−/−mice.CONCLUSIONS:Inhibition of ASGR1 inhibits atherosclerosis in Western diet–fedApoE−/−mice, suggesting that inhibiting ASGR1 may serve as a novel therapeutic strategy to treat atherosclerosis and cardiovascular diseases.

Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR that is shed by Furin

Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin

Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion

ASGR1 deficiency improves atherosclerosis but alters liver metabolism in ApoE-/- mice

ASGR1 deficiency diverts lipids toward adipose tissue but results in liver damage during obesity

ASGR1 Deficiency Inhibits Atherosclerosis in Western Diet–Fed ApoE−/− Mice by Regulating Lipoprotein Metabolism and Promoting Cholesterol Efflux

ASGR1 is a promising target for lipid reduction in pigs with PON2 as its inhibitor

Differential cholesterol uptake in liver cells: A role for PCSK9

Scavenger receptor a mediates glycated LDL transcytosis across endothelial cells to promote atherosclerosis

Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9

Deficiency of ASGR1 promotes liver injury by increasing GP73-mediated hepatic endoplasmic reticulum stress

Hepatic S1P Deficiency Lowers Plasma Cholesterol Levels in Apob-Containing Lipoproteins when LDLR Function is Compromised.

Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening

Deficiency of ASGR1 in pigs recapitulates reduced risk factor for cardiovascular disease in humans

Beyond conventional treatment: ASGR1 Leading the new era of hypercholesterolemia management

Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity

ASGR1 is a candidate receptor for SARS-CoV-2 that promotes infection of liver cells

Sterol regulatory element binding proteins downregulate LDL receptor-related protein (LRP1) expression and LRP1-mediated aggregated LDL uptake by human macrophages

Insights into PCSK9-LDLR Regulation and Trafficking via the Differential Functions of MHC-I Proteins HFE and HLA-C

Geranylgeranyl Isoprenoids and Hepatic Rap1a Regulate Basal and Statin-Induced Expression of PCSK9

Atherosclerosis-associated hepatic secretion of VLDL but not PCSK9 is dependent on cargo receptor protein Surf4